The University of Chicago Header Logo

Connection

Jeremy Segal to Mutation

This is a "connection" page, showing publications Jeremy Segal has written about Mutation.
Connection Strength

1.247
  1. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097.
    View in: PubMed
    Score: 0.304
  2. BAP1-Mutated Clear Cell Renal Cell Carcinoma. Am J Clin Pathol. 2021 04 26; 155(5):718-728.
    View in: PubMed
    Score: 0.084
  3. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing. Mol Diagn Ther. 2019 12; 23(6):791-802.
    View in: PubMed
    Score: 0.077
  4. Next-generation sequencing identifies 2 genomically distinct groups among pyloric gland adenomas. Hum Pathol. 2020 03; 97:103-111.
    View in: PubMed
    Score: 0.076
  5. insiM: in silico Mutator Software for Bioinformatics Pipeline Validation of Clinical Next-Generation Sequencing Assays. J Mol Diagn. 2019 01; 21(1):19-26.
    View in: PubMed
    Score: 0.071
  6. Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations? Am J Surg Pathol. 2018 07; 42(7):911-917.
    View in: PubMed
    Score: 0.069
  7. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 05 04; 9(1):1793.
    View in: PubMed
    Score: 0.069
  8. Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. J Mol Diagn. 2017 01; 19(1):43-56.
    View in: PubMed
    Score: 0.062
  9. Unclassified renal cell carcinoma with tubulopapillary architecture, clear cell phenotype, and chromosome 8 monosomy: a new kid on the block. Virchows Arch. 2016 Jul; 469(1):81-91.
    View in: PubMed
    Score: 0.060
  10. Polyglucosan bodies in intramuscular nerve branches are a poor predictor of GBE1 mutation and adult polyglucosan body disease. Muscle Nerve. 2016 Mar; 53(3):473-5.
    View in: PubMed
    Score: 0.059
  11. Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma. Int J Gynecol Pathol. 2021 Mar 01; 40(2):156-164.
    View in: PubMed
    Score: 0.021
  12. Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case. Pathology. 2021 Oct; 53(6):790-793.
    View in: PubMed
    Score: 0.021
  13. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study. Hum Pathol. 2021 09; 115:84-95.
    View in: PubMed
    Score: 0.021
  14. Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies. Blood Adv. 2020 10 27; 4(20):5269-5284.
    View in: PubMed
    Score: 0.020
  15. Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Adv. 2020 10 13; 4(19):4873-4886.
    View in: PubMed
    Score: 0.020
  16. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study. Am J Surg Pathol. 2020 07; 44(7):943-954.
    View in: PubMed
    Score: 0.020
  17. Follicular Thyroid Neoplasms: Comparison of Clinicopathologic and Molecular Features of Atypical Adenomas and Follicular Thyroid Carcinomas. Am J Surg Pathol. 2020 07; 44(7):881-892.
    View in: PubMed
    Score: 0.020
  18. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
    View in: PubMed
    Score: 0.020
  19. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study. Genes Chromosomes Cancer. 2020 08; 59(8):484-494.
    View in: PubMed
    Score: 0.020
  20. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol. 2019 08; 94(8):921-928.
    View in: PubMed
    Score: 0.019
  21. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
    View in: PubMed
    Score: 0.018
  22. Integrating a Large Next-Generation Sequencing Panel into the Clinical Diagnosis of Gliomas Provides a Comprehensive Platform for Classification from FFPE Tissue or Smear Preparations. J Neuropathol Exp Neurol. 2019 03 01; 78(3):257-267.
    View in: PubMed
    Score: 0.018
  23. Cribriform-Morular Variant of Papillary Thyroid Carcinoma With Poorly Differentiated Features: A Case Report With Immunohistochemical and Molecular Genetic Analysis. Int J Surg Pathol. 2019 May; 27(3):294-304.
    View in: PubMed
    Score: 0.018
  24. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth. Arch Pathol Lab Med. 2018 07; 142(7):838-850.
    View in: PubMed
    Score: 0.017
  25. Synchronous and Metastatic Papillary and Follicular Thyroid Carcinomas with Unique Molecular Signatures. Endocr Pathol. 2018 Mar; 29(1):9-14.
    View in: PubMed
    Score: 0.017
  26. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841.
    View in: PubMed
    Score: 0.015
  27. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science. 2014 Jan 17; 343(6168):309-13.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.